Global and annual to send case China of hepatocarcinoma and

Global and annual to send case China of hepatocarcinoma and exceed 50% newly
It is reported ' Reporter Chen Qing) Bayer medicines and health protection Company announced in Shanghai yesterday, it researched and developed oral anticancer drug Ji Mei (Sole was not a Buddhist nun) more that produced Has already got national food medicines in China and supervised the administration bureau sanctioning, for liver cell cancer or the hepatocarcinoma patient's clinical treatment that can not excised. This is global and first up until now sanctioned being used in the therapeutic medicine of hepatocarcinoma system of later period, also only one is verified the medicine of total life cycle of patient of hepatocarcinoma of later period of very prominent extension.

Hepatocarcinoma is the sixth largest common cancer in the world, it is the third largest main factor in the relevant death of global cancer too. In more than 620,000 cases of hepatocarcinoma patient that and the whole world diagnoses newly every year, 55% happen in China. 30% patient have an opportunity, undergo an operation treatment only in numerous the intersection of hepatocarcinoma and patient, lack it to the later period effective therapeutic medicine of hepatocarcinoma for a long time.

An international many centre III stage placeboes verify to shining on the bed test, al later period of system the hepatocarcinomaoes verify to shining on the bed test, Result reveal compared with placebo, how can make later period the intersection of liver and cell cancer or send hepatocarcinoma total life cycle prominent 44% extension of patient originally while being beautiful while being lucky.

Academician, the second army medical university eastern liver and gall surgical director Professor Wu MengChao of Chinese Academy of Sciences say, in 9 clinical research of III stage of Asian-Pacific area which cities participates in together including Beijing, Shanghai, Guangzhou,etc., compared with placebo, how make later period the intersection of liver and cell cancer of here or send hepatocarcinoma total life cycle prominent 47.3% extension of patient originally while being beautiful while being lucky, make disease of patient these develop the intersection of time and prominent 74% extension still.

It shows, the appearance of the therapeutic medicine of hepatocarcinoma system in new later period, will undoubtedly bring the hope for more patients that Wu Meng exceeds.

Global and annual to send case China of hepatocarcinoma and exceed 50% newly